新华制药(000756.SZ)获恩他卡朋片药品注册证

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration certificate of Entacapone tablets, which can be used as an adjunct therapy for Parkinson's disease when standard medications are insufficient [1] Group 1 - The approved product, Entacapone, is indicated for use alongside standard medications such as Levodopa/benserazide or Levodopa/carbidopa [1] - Entacapone is specifically aimed at treating Parkinson's disease and addressing motor fluctuations that cannot be controlled by existing therapies [1]